Company / Return on Equity (ROE)
BioXcel Therapeutics, Inc. Return on Equity (ROE) History
FY2022-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-215.9%
FY2023
5-year range
-215.9% / -48.2%
FY2022-FY2023
Trend
-347.6%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
BioXcel Therapeutics, Inc. reports negative total equity of -215.9% in FY2023. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-215.9% in FY2023.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2023, return on equity (roe) decreased 347.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | -215.9% | -347.6% |
| FY2022 | -48.2% | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026